the subject is excluded from the trial if any of the following criteria apply: 1. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited \< 24 hours prior to start of imp treatment 2. requiring mechanical ventilation at screening or it is expected within 24 h after inclusion 3. expected survival time \< 72 hours for any reason 4. positive pregnancy test 5. breastfeeding woman 6. presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) \<60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) 7. known hypersensitivity to the trial drug, the metabolites, or formulation excipient 8. history or presence of drug or alcohol abuse 9. history or presence of diseases of thyroid gland

the subject is excluded from the trial if any of the following criteria apply: 1. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited \< 24 hours prior to start of imp treatment 2. requiring mechanical ventilation at screening or it is expected within 24 h after inclusion 3. expected survival time \< 72 hours for any reason 4. positive pregnancy test 5. breastfeeding woman 6. presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) \<60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) 7. known hypersensitivity to the trial drug, the metabolites, or formulation excipient 8. history or presence of drug or alcohol abuse 9. history or presence of diseases of thyroid gland

the subject is excluded from the trial if any of the following criteria apply: concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to start of imp treatment requiring mechanical ventilation at screening or it is expected within 24 h after inclusion expected survival time < 72 hours for any reason positive pregnancy test breastfeeding woman presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) <60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) known hypersensitivity to the trial drug, the metabolites, or formulation excipient history or presence of drug or alcohol abuse history or presence of diseases of thyroid gland

the subject is excluded from the trial if any of the following criteria apply: concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to start of imp treatment requiring mechanical ventilation at screening or it is expected within 24 h after inclusion expected survival time < 72 hours for any reason positive pregnancy test breastfeeding woman presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) <60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) known hypersensitivity to the trial drug, the metabolites, or formulation excipient history or presence of drug or alcohol abuse history or presence of diseases of thyroid gland

the subject is excluded from the trial if any of the following criteria apply: 1. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to start of imp treatment 2. requiring mechanical ventilation at screening or it is expected within 24 h after inclusion 3. expected survival time < 72 hours for any reason 4. positive pregnancy test 5. breastfeeding woman 6. presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) <60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) 7. known hypersensitivity to the trial drug, the metabolites, or formulation excipient 8. history or presence of drug or alcohol abuse 9. history or presence of diseases of thyroid gland

the subject is excluded from the trial if any of the following criteria apply: 1. concurrent treatment with other agents with actual or possible direct acting antiviral activity against sars-cov-2 is prohibited < 24 hours prior to start of imp treatment 2. requiring mechanical ventilation at screening or it is expected within 24 h after inclusion 3. expected survival time < 72 hours for any reason 4. positive pregnancy test 5. breastfeeding woman 6. presence of renal dysfunction defined as estimated glomerular filtration rate (egfr) <60 ml/min, total bilirubin ≥ 2.0 mg/dl, thyroid stimulating hormone (tsh) outside normal range and / or aspartate aminotransferase (asat)/ alanine aminotransferase (alat) above threefold upper limit of normal range (known from patients medical history) 7. known hypersensitivity to the trial drug, the metabolites, or formulation excipient 8. history or presence of drug or alcohol abuse 9. history or presence of diseases of thyroid gland